Eli Lilly LLY Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Jardiance | $1.11B+9.9% | $768.6M-35.9% | $959M+39.7% | $690M-10.3% | $1.01B+47.7% | |
| Mounjaro | $8.66B+125% | $7.41B+110% | $6.52B+109% | $5.2B+68.2% | $3.84B+113% | |
| Neuroscience | $382M+40.4% | $459.2M+16.7% | $315.7M-10.3% | $344M+1.3% | $272M-30.1% | |
| Other cardiometabolic health | $905M-4.2% | $1.02B-16.6% | $1.06B+1.4% | $980.4M-15.9% | $945M-7.9% | |
| Other immunology | $470M+44.2% | $489M+44.1% | $460.9M+50.6% | $408M+58.3% | $326M+41.8% | |
| Other oncology | $966M+22.4% | $1B+0.6% | $937.4M+8.7% | $924.3M+11.8% | $789M+3.9% | |
| Taltz | $733M-3.8% | $1.05B+10.6% | $901.5M+2.5% | $847.6M+2.8% | $762M+26.1% | |
| Trulicity | $919M-16.1% | $1.04B-17.1% | $1.05B-19.2% | $1.09B-12.3% | $1.1B-24.8% | |
| Verzenio | $1.3B+12.3% | $1.6B+3.2% | $1.47B+7.4% | $1.49B+11.8% | $1.16B+10.3% | |
| Zepbound | $4.16B+79.9% | $4.26B+123% | $3.59B+185% | $3.38B+172% | $2.31B+347% | |
| Potential achievements by Product | ||||||
| Boehringer Ingelheim | $660M+8.2% | —— | $410M— | —— | $610M— | |
| Ebglyss | $1.2B-4.0% | $1.2B-4.0% | $1.25B0.0% | $1.25B0.0% | $1.25B0.0% | |
| R&D by Product | ||||||
| Early-stage | $1.27B+27.9% | $1.49B+42.2% | $1.25B+25.6% | $1.16B+12.7% | $990M+16.2% | |
| Late-stage | $2.24B+28.7% | $2.32B+17.1% | $2.22B+27.4% | $2.18B+29.3% | $1.74B+4.4% | |
| Revenue by Geography | ||||||
| China | $693M+53.7% | $473.2M+10.4% | $560.4M+21.9% | $465.9M+17.9% | $451M+19.9% | |
| Europe | $3.65B+52.6% | $3.1B+26.5% | $3.5B+115% | $2.57B+83.4% | $2.39B+65.8% | |
| Japan | $571M+42.0% | $654.8M+17.1% | $554.7M+29.3% | $521M+12.6% | $402M+10.5% | |
| Outside U.S. | $7.68B+81.2% | $6.41B+42.5% | $6.3B+73.8% | $4.74B+36.8% | $4.24B+37.9% | |
| Rest of world | $2.77B+178% | $2.19B+106% | $1.69B+52.3% | $1.18B-2.0% | $997M+11.7% | |
| U.S. | $12.12B+42.8% | $12.88B+42.6% | $11.3B+44.6% | $10.81B+38.0% | $8.49B+49.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Eli Lilly break its business down?
- Eli Lilly (LLY) reports revenue by product across 10 parts — Jardiance, Mounjaro, Neuroscience, Other cardiometabolic health and Other immunology. Each is extracted from the segment footnotes and tracked over time.
- Where does Eli Lilly's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Eli Lilly's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
